GB Sciences https://validator.w3.org/feed/docs/rss2.html News Room News from Washington D.C. 400% Sales Increase GB Sciences is “Happy” Tissue Culture Propagation Breakthrough GB Sciences: Research is in our Corporate DNA Dr. Small-Howard invited to Neuroscience Forum GB Sciences Partners with Wellcana Group in Louisiana CEO John Poss Interview YouTube: Spinach Veins Replace Human Blood Vessels New VP and General Counsel Home Video: CEO John Poss on a “Small but Complex” Company Louisiana House backs expansion of medical cannabis program The State of Alaska: Boom or Bust? Video: What is a Cannabinoid? CNN: Patients turn to pot over pills COLORADO MISSOURI Cannabis: the Early Years and What They Teach Us VERMONT’S GARDENING EXPERIMENT GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM)) GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue Statement From LSU AgCenter on False Allegations Made by LDAF Commissioner GB Sciences Team to Present at Digital Hollywood Forum Nine Pharmacies to Serve Louisiana GB Sciences Strengthens Compliance Program First Quarter Revenue GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson’s Disease and Neuropathic Pain GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated Research Collaboration in Spain GBScience Forms Science Advisory Board Scientific Advisory Board Expands GB Sciences and Parkinson’s Disease Video: CEO John Poss on Jeff Sessions GB Seeks Minor Cannabinoids for Patient Studies Video: CEO John Poss talks CBD, Cura, Hemp Video: CEO John Poss talks Rec vs. Science Video: CEO John Poss talks European Trials Radio Interview: John Poss on Bill Martinez Live Researchers Name GB Sciences in Top 10 Peer-Reviewed Article for American Heart Association GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Catalent to Provide Parkinson’s Therapy Delivery Systems DEA Rescheduling Benefits GB Sciences GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc. GB Sciences Files New Provisional Patent